Skip to main content
KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc. — Investor Relations & Filings

Ticker · KRMD ISIN · US7599101026 US Manufacturing
Open in API
Filings indexed 922 across all filing types
Latest filing 2025-04-07 Board/Management Inform…
Country US United States of America
Listing US KRMD

About KORU Medical Systems, Inc.

https://www.korumedical.com/

KORU Medical Systems is a medical technology company that designs, develops, manufactures, and commercializes subcutaneous infusion solutions. The company's primary offering is the Freedom™ Infusion System, which includes syringe infusion pumps and related accessories. These systems are engineered for the delivery of large-volume subcutaneous drugs, such as immunoglobulins, to treat patients with chronic illnesses. KORU Medical Systems focuses on providing patient-centric solutions that facilitate safe and effective home-based infusion therapy, aiming to enhance patient quality of life by offering greater freedom and flexibility in treatment management.

Recent filings

Filing Released Lang Actions
FORM 8-K CURRENT REPORT FOR 04-03-2025
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content includes the resignation of a Chief Commercial Officer and appointment of an interim leader, which is a change in senior management. There is also a reiteration of full-year revenue guidance, but no detailed financial statements or comprehensive financial analysis are provided. The document is about management changes and some forward-looking statements but does not contain full financial reports or earnings releases. Therefore, the most appropriate classification is 'Board/Management Information' (MANG), as it primarily announces changes in the company's senior management.
2025-04-07 English
FORM 8-K CURRENT REPORT FOR 03-31-2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2025, reporting an amendment to a loan and security agreement. It details changes to the credit facility terms, including maturity extension and financial covenant adjustments. The document is a current report on a material definitive agreement, which is a financing update rather than a full financial report. The length is 4126 characters, which is relatively short and focused on a financing amendment. There is no comprehensive financial data or earnings information, so it is not an Annual Report, Interim Report, or Earnings Release. The content fits the Capital/Financing Update category, which covers updates on company fundraising, financing activities, or capital structure changes.
2025-04-04 English
SCHEDULE 14A DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2025-04-04 English
FORM 4 FOR 04-02-2025
Director's Dealing
2025-04-02 English
FORM 4 FOR 04-02-2025
Director's Dealing
2025-04-02 English
FORM 4 FOR 04-02-2025
Director's Dealing
2025-04-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.